Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: ISRAEL

Sector: Biotechnology

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm`s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Website: mediwound.com


  • Good financial results growth rate 12.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.9%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 68.3% (LTM)
  • Share price is 96.2% higher than minimum and 36.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 0.3x)
  • For the last 3 months insiders bought company shares on $0.1 mln (0.166% of cap.)

Key Financials (Download financials)

Ticker: MDWD
Share price, USD:  (0.0%)14.09
year average price 17.99  


year start price 20.42 2025-06-13

max close price 21.09 2025-07-10

min close price 13.77 2026-06-02

current price 14.09 2026-06-12
Common stocks: 5 819 310

Dividend Yield:  0.0%
EV / Sales: 0.9x
Margin (EBITDA LTM / Revenue): -114.3%

Target EV / EBITDA (hist percentile): 0.3x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 82
Net Debt ($m): -50
EV (Enterprise Value): 32
EBITDA LTM (млн $): -40
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-20zacks.com

MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates

2025-09-29globenewswire.com

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

2025-09-25globenewswire.com

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

2025-09-02globenewswire.com

MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

2025-09-02seekingalpha.com

MediWound Is A Buy Opportunity On The Dip

2025-08-14seekingalpha.com

MediWound Ltd. (MDWD) Q2 2025 Earnings Call Transcript

2025-08-13globenewswire.com

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

2025-05-21zacks.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

2025-03-19seekingalpha.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

2025-03-19zacks.com

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-20 2025-08-14 2025-05-21 2024-11-26 2024-08-14 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2025-11-20 07:04:59 2025-08-14 07:05:26 2025-05-21 07:07:42 2025-03-19 07:15:37 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 08:08:34 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2023-03-16 07:05:51 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00 2022-03-17 07:08:14 2021-02-25 07:53:57
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 5M 6M 4M 20M 4M 5M 5M 19M 5M 5M 4M 26M 6M 5M 4M 24M 22M
costOfRevenue 5M 4M 3M 18M 4M 5M 4M 16M 4M 4M 3M 14M 3M 4M 3M 16M 15M
grossProfit 896 000 1M 738 000 2M 677 000 447 000 607 000 3M 896 000 1M 826 000 12M 2M 1M 1M 8M 7M
grossProfitRatio 0.165 0.235 0.187 0.155 0.088 0.122 0.188 0.238 0.217 0.419 0.238 0.331
researchAndDevelopmentExpenses 3M 3M 3M 8M 3M 2M 1M 7M 2M 2M 2M 10M 3M 2M 2M 10M 7M
generalAndAdministrativeExpenses 0 0 2M 0 2M 2M 2M 0 0 0 0 0 3M 1M 0 0 0
sellingAndMarketingExpenses 0 0 1M 0 1M 1M 1M 0 0 0 0 0 0 935 000 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 4M 3M 13M 3M 3M 3M 11M 3M 3M 3M 10M 3M 2M 2M 9M 8M
otherExpenses 0 0 4000 0 0 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 7M 7M 6M 21M 6M 5M 4M 18M 4M 5M 5M 20M 6M 4M 5M 19M 16M
costAndExpenses 12M 11M 9M 40M 9M 10M 9M 34M 8M 9M 8M 34M 9M 8M 8M 35M 31M
interestIncome 4M 429 000 5M 2M 0 582 000 0 2M 877 000 6M 676 000 270 000 0 11 000 11 000 297 000
interestExpense 0 8M 0 561 000 0 2M 6M 335 000 0 893 000 -676 000 162 000 684 000 687 000 301 000 167 000 200 000
depreciationAndAmortization 418 000 394 000 358 000 1M 361 000 357 000 368 000 1M 339 000 315 000 303 000 1M 338 000 329 000 321 000 1M 1M
ebitda -2M -5M -5M -28M -5M -4M -3M -5M -3M -4M -4M -18M -3M -3M -3M -12M -8M
ebitdaratio -0.402 -0.857 -1.231 -1.084 -0.815 -0.678 -0.562 -0.774 -1.069 -0.547 -0.714 -0.672
operatingIncome -7M -6M -5M -19M -5M -4M -4M -16M -3M -4M -4M -8M -4M -3M -3M -11M -9M
operatingIncomeRatio -1.202 -1.001 -1.321 -1.167 -0.886 -0.752 -0.633 -0.84 -1.149 -0.605 -0.721 -0.745
totalOtherIncomeExpensesNet 4M -8M 5M -11M -5M -2M -6M 9M 877 000 5M 676 000 -12M -684 000 -985 000 -301 000 -2M -436 000
incomeBeforeTax -3M -13M -721 000 -30M -10M -6M -10M -7M -2M 928 000 -4M -20M -4M -4M -4M -14M -9M
incomeBeforeTaxRatio -0.479 -2.327 -0.182 -2.356 -1.246 -1.955 -0.45 0.194 -0.971 -0.723 -0.932 -0.813
incomeTaxExpense 53 000 38 000 5000 61 000 21 000 -2000 24 000 185 000 48 000 12 000 5000 78 000 5000 4000 4000 27 000 0
netIncome -3M -13M -726 000 -30M -10M -6M -10M -7M -2M 916 000 -4M -20M -4M -4M -4M -14M -9M
netIncomeRatio -0.488 -2.333 -0.184 -2.361 -1.245 -1.96 -0.46 0.192 -0.972 -0.724 -0.933 -0.814
eps -0.24 -1.23 -0.07 -3.03 -0.98 -0.68 -1.05 -0.75 -0.24 0.1 -0.44 -3.93 -0.88 -0.91 -0.018 -3.48 -2.38
epsdiluted -0.24 -1.23 -0.067 -0.98 -0.68 -1.05 -0.24 0.1 -0.44 -0.88 -0.91 -0.018
weightedAverageShsOut 11M 11M 10M 10M 11M 9M 9M 9M 9M 9M 8M 5M 5M 5M 201M 4M 4M
weightedAverageShsOutDil 11M 11M 11M 10M 11M 9M 9M 9M 9M 9M 8M 5M 5M 5M 201M 4M 4M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-19 2024-03-21 2023-03-16 2022-03-17 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 1M 2M 108 000 -156 000 97 000
ebit -30M -6M -19M -13M -9M
nonOperatingIncomeExcludingInterest 10M -9M 12M 2M 235 999
netIncomeFromContinuingOperations -30M -7M -20M -14M -9M
netIncomeFromDiscontinuedOperations 0 0 0 0 80 000
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -30M -7M -20M -14M -9M
epsDiluted -3.03 -0.75 -3.93 -3.48 -2.38

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-20 2025-08-14 2025-05-21 2024-11-26 2024-08-14 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2025-11-20 07:04:59 2025-08-14 07:05:26 2025-05-21 07:07:42 2025-03-19 07:15:37 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 08:08:34 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2023-03-16 07:05:51 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00 2022-03-17 07:08:14 2021-02-25 07:53:57
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 59M 1M 38M 9M 0 4M 36M 12M 9M 51M 51M 34M 0 8M 0 11M 17M
shortTermInvestments 0 31M 0 34M 0 25M 0 30M 36M 32M 6M 0 0 3M 0 0 4M
cashAndShortTermInvestments 59M 32M 38M 43M 46M 29M 36M 42M 46M 51M 57M 34M 18M 10M 17M 11M 22M
netReceivables 6M 7M 5M 6M 5M 5M 5M 4M 4M 4M 4M 10M 5M 4M 3M 2M 3M
inventory 4M 4M 4M 3M 3M 3M 3M 3M 4M 3M 3M 2M 2M 2M 2M 1M 1M
otherCurrentAssets 0 0 0 0 0 0 0 167 000 0 0 0 363 000 0 168 000 0 0 257 000
totalCurrentAssets 70M 43M 47M 52M 54M 37M 44M 50M 53M 58M 63M 46M 24M 17M 22M 15M 26M
propertyPlantEquipmentNet 24M 23M 21M 21M 20M 19M 17M 16M 13M 6M 5M 4M 4M 4M 4M 4M 5M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 50 000 66 000 83 000 99 000 0 132 000 149 000 165 000 182 000 198 000 0 231 000 0 0 0 297 000 363 000
goodwillAndIntangibleAssets 50 000 66 000 83 000 99 000 116 000 132 000 149 000 165 000 182 000 198 000 215 000 231 000 248 000 264 000 281 000 297 000 363 000
longTermInvestments 465 000 490 000 0 439 000 0 238 000 238 000 490 000 483 000 277 000 0 364 000 0 0 0 469 000 0
taxAssets 0 0 0 0 0 0 0 0 -483 000 -277 000 0 -364 000 0 0 0 -469 000 0
otherNonCurrentAssets 0 0 485 000 0 484 000 453 000 446 000 183 000 483 000 -6M 305 000 -4M 230 000 230 000 230 000 -4M -5M
totalNonCurrentAssets 25M 24M 22M 21M 21M 20M 18M 17M 14M 6M 5M 4M 4M 4M 4M 5M 5M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 94M 67M 69M 73M 75M 57M 62M 66M 67M 64M 69M 50M 29M 21M 26M 20M 31M
accountPayables 9M 6M 5M 4M 3M 3M 4M 4M 4M 4M 3M 6M 4M 5M 6M 5M 3M
shortTermDebt 1M 822 000 0 418 000 0 0 2M 0 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 12 000 0 0 1 24 000 0 0 0 63 000 0 0 0 543 000 462 000
otherCurrentLiabilities 17M 22M 17M 18M 22M 20M 17M 2M 5M 5M 6M 4M 5M 6M 6M 4M 3M
totalCurrentLiabilities 26M 29M 22M 27M 26M 23M 22M 11M 8M 8M 9M 12M 9M 10M 11M 11M 8M
longTermDebt 8M 8M 6M 0 6M 6M 6M 0 6M 677 000 743 000 0 952 000 1M 1M 0 0
deferredRevenueNonCurrent 0 758 000 736 000 736 000 0 0 0 0 0 0 0 0 31 000 61 000 91 000 119 000 1M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 456 000 9M 9M 9M 8M 10M 3M 10M 20M 20M 25M 26M 14M 12M 12M 12M 13M
totalNonCurrentLiabilities 9M 18M 16M 16M 15M 17M 9M 17M 26M 21M 26M 27M 18M 13M 13M 14M 16M
otherLiabilities 0 0 0 0 0 0 0 7M 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 8M 8M 6M 7M 6M 6M 6M 6M 6M 677 000 743 000 846 000 952 000 1M 1M 1M 2M
totalLiabilities 35M 47M 38M 42M 40M 39M 31M 35M 34M 29M 35M 39M 27M 23M 24M 24M 24M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 216 000 0 215 000 0 186 000 23M 184 000 33M 184 000 0 143 000 0 93 000 0 75 000 75 000
retainedEarnings 0 -219M 0 -205M 0 -191M 0 -175M 0 -171M 0 -168M 0 -156M 0 -149M -135M
accumulatedOtherComprehensiveIncomeLoss 0 -21 000 0 -11 000 0 -8000 0 -18 000 0 -14 000 0 -5000 0 3000 0 -19 000 -40 000
othertotalStockholdersEquity 50M 239M 31M 34M 209M 0 0 206M 0 2M 0 2M
totalStockholdersEquity 50M 20M 31M 31M 34M 18M 23M 32M 33M 35M 33M 11M 2M -2M 2M -5M 7M
totalEquity 50M 20M 31M 31M 34M 18M 23M 32M 33M 35M 33M 11M 2M -2M 2M -5M 7M
totalLiabilitiesAndStockholdersEquity 94M 67M 69M 75M 57M 62M 67M 64M 69M 29M 21M 26M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 94M 67M 69M 73M 75M 57M 62M 66M 67M 64M 69M 50M 29M 21M 26M 20M 31M
totalInvestments 465 000 32M 0 34M 0 26M 238 000 30M 36M 32M 6M 364 000 0 0 0 469 000 4M
totalDebt 9M 8M 6M 7M 6M 6M 8M 6M 6M 677 000 743 000 846 000 952 000 1M 1M 1M 2M
netDebt -50M -24M -32M -2M 6M 4M -28M -6M -3M -50M -50M -33M 952 000 -7M 1M -10M -16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-19 2024-03-21 2023-03-16 2022-03-17 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 5M 4M 9M 2M 3M
otherReceivables 1M 719 000 363 000 488 000 73 000
prepaids 458 000 722 000 0 439 000 389 000
totalPayables 4M 6M 6M 5M 3M
otherPayables 312 000 1M 0 0 0
accruedExpenses 4M 3M 2M 2M 2M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 7M 6M 846 000 1M 2M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 236M 206M 179M 144M 142M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2020-12-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-20 2025-08-14 2025-05-21 2024-11-26 2024-08-14 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2025-11-20 07:04:59 2025-08-14 07:05:26 2025-05-21 07:07:42 2025-03-19 07:15:37 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 08:08:34 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2023-03-16 07:05:51 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00 2022-03-17 07:08:14 2021-02-25 07:53:57
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome -3M -13M -726 000 -30M -10M -6M -10M -7M -2M 916 000 -4M -20M -4M -4M -4M -14M -9M
depreciationAndAmortization 418 000 394 000 358 000 1M 361 000 357 000 368 000 1M 339 000 315 000 303 000 1M 338 000 329 000 321 000 1M 1M
deferredIncomeTax 0 0 0 0 0 0 0 0 -701 000 -5M 0 0 0 0 0 -124 000 -373 000
stockBasedCompensation 0 862 000 844 000 3M 1M 758 000 512 000 2M 311 000 712 000 619 000 2M 707 000 252 000 345 000 2M 1M
changeInWorkingCapital 2M -1M -62 000 1M 98 000 -295 606 -2M 2M -539 000 -2M 4M -7M -2M -2M -2M 162 000 -61 000
accountsReceivables 808 606 -2M 1M -1M -177 000 416 284 -238 000 5M 71 000 -707 000 7M -8M -421 000 -1M -579 000 929 000 1M
inventory -596 401 -263 000 -888 000 187 000 184 000 103 000 -448 000 -906 000 -526 000 -579 000 -583 000 -721 000 139 000 -37 000 -710 000 257 000 141 000
accountsPayables 2M 794 000 -103 000 406 000 -48 000 -522 405 -1M -594 000 -51 000 312 000 -2M 414 000 -1M -272 000 283 000 2M -1M
otherWorkingCapital 387 000 3000 -147 000 2M 139 000 -292 485 260 000 -928 000 -33 000 -924 000 -480 000 645 000 -646 000 0 0 -3M -492 000
otherNonCashItems -3M 7M -5M 11M 5M 2M 10M -9M -465 000 -416 000 -388 000 12M 759 000 552 000 622 000 2M 323 000
netCashProvidedByOperatingActivities -3M -6M -4M -14M -4M -4M -4M -10M -3M -5M 652 000 -12M -5M -5M -4M -9M -7M
investmentsInPropertyPlantAndEquipment -1M -1M -959 000 -6M -1M -3M -1M -6M -2M -1M -2M -555 000 -83 000 -138 000 -160 000 -489 000 -923 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 3M 0 0 -14M 0 -1M 0 -5M -26M 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 5M 3M 0 0 0 0 0 0 0 0 0 0 0 0 0 4M 18M
otherInvestingActivites 0 203 825 -2M 461 000 6M -525 000 361 874 805 407 -6M 3000 -2M 0
netCashUsedForInvestingActivites 4M 5M -3M -14M 3M -2M -6M -26M -7M -80 000 -3M -160 000
debtRepayment 0 -289 000 -248 000 -228 000 -214 000 -244 000 -240 000 -157 000 -177 000 -181 000 -172 000 -178 000
commonStockIssued 32M 870 334 0 22M -499 000 499 000 -11 204 -69 256 25M 0 0 10M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 -556 000 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -454 617 -32 334 -114 000 -1M 111 000 -954 000 -487 000 -178 744 -727 000 12M 0 -162 000
netCashUsedProvidedByFinancingActivities 32M 549 000 -362 000 21M -103 000 -699 000 -727 000 -405 000 24M 12M -728 000 10M
effectOfForexChangesOnCash 25M 2000 19 000 -84 000 18 000 -15 000 -89 000 -160 000 -81 000 -120 000 -337 000 -549 000 45 000 -303 000 -247 000 88 000 273 000
netChangeInCash 58M -300 000 -8M -3M 3M -896 000 24M -22M -10M -32M 17M 23M 7M -9M 6M -6M 10M
cashAtEndOfPeriod 59M 1M 1M 9M 6M 4M 36M 12M 9M 19M 51M 34M 15M 8M 17M 11M 17M
cashAtBeginningOfPeriod 1M 1M 9M 12M 4M 5M 12M 34M 19M 51M 34M 11M 8M 17M 11M 17M 7M
operatingCashFlow -3M -6M -4M -14M -4M -4M -4M -10M -3M -5M 652 000 -12M -5M -5M -4M -9M -7M
capitalExpenditure -1M -1M -959 000 -6M -1M -3M -1M -6M -2M -1M -2M -555 000 -83 000 -138 000 -160 000 -489 000 -923 000
freeCashFlow -4M -7M -5M -20M -5M -7M -5M -17M -5M -6M -853 000 -12M -5M -5M -4M -9M -8M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-19 2024-03-21 2023-03-16 2022-03-17 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -2M -28M 74 000 35 000 274 000
netCashProvidedByInvestingActivities -8M -34M -481 000 4M 17M
netDebtIssuance -928 000 0 0 0 -508 000
longTermNetDebtIssuance -928 000 0 0 -693 000 -508 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 22M 25M 38M 0 0
netCommonStockIssuance 22M 25M 38M 0 0
commonStockIssuance 22M 25M 38M 3000 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -2M -2M -3M -1M -121 000
netCashProvidedByFinancingActivities 19M 23M 36M -1M -629 000
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-20 ET (fiscal 2025 q3)
2025 q2
2025-08-14 ET (fiscal 2025 q2)
2025 q1
2025-05-21 ET (fiscal 2025 q1)
2024 q4
2025-03-19 ET (fiscal 2024 q4)
2024 q3
2024-11-26 ET (fiscal 2024 q3)
2024 q2
2024-08-14 ET (fiscal 2024 q2)
2024 q1
2024-05-29 ET (fiscal 2024 q1)
2023 q4
2024-03-21 ET (fiscal 2023 q4)
2023 q3
2023-11-21 ET (fiscal 2023 q3)
2023 q2
2023-08-16 ET (fiscal 2023 q2)
2023 q1
2023-05-30 ET (fiscal 2023 q1)
2022 q4
2023-03-16 ET (fiscal 2022 q4)
2022 q3
2022-11-15 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-17 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-27 11:00 ET
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 ET
MediWound to Report First Quarter 2026 Financial Results
2026-04-13 11:30 ET
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
2026-04-07 ET
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
2026-04-02 ET
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
2026-03-05 ET
MediWound Files Annual Report on Form 20-F
2026-03-05 ET
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-19 ET
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
2026-02-17 ET
MediWound to Present at Upcoming Investor Conferences
2026-01-12 ET
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
2025-12-10 ET
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
2025-11-20 12:00 ET
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-05 ET
MediWound to Report Third Quarter 2025 Financial Results
2025-11-03 ET
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
2025-09-29 ET
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
2025-09-25 ET
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
2025-09-02 ET
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
2025-08-20 ET
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-14 ET
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-13 ET
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
2025-08-04 ET
MediWound to Report Second Quarter 2025 Financial Results
2025-05-21 ET
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-13 ET
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
2025-05-05 ET
MediWound to Report First Quarter 2025 Financial Results
2025-04-28 ET
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
2025-03-19 ET
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-03-03 ET
MediWound to Report Fourth Quarter and Full Year 2024 Financial Results
2025-02-25 ET
MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care
2025-02-24 ET
MediWound to Present at the 45th Annual TD Cowen Health Care Conference
2025-02-12 ET
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
2025-02-04 ET
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
2025-01-22 ET
BioHarvest Announces Appointment of Sharon Malka to Board of Directors
2024-12-17 ET
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
2024-11-26 ET
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
2024-11-12 13:00 ET
MediWound to Report Third Quarter 2024 Financial Results
2024-10-10 11:00 ET
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
2024-10-08 12:00 ET
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
2024-09-03 12:00 ET
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-15 20:15 ET
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
2024-08-14 11:00 ET
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
2024-08-05 11:30 ET
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
2024-08-02 12:00 ET
MediWound to Report Second Quarter 2024 Financial Results
2024-07-29 12:00 ET
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
2024-07-16 11:30 ET
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
2024-07-15 11:32 ET
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
2024-07-15 11:00 ET
MediWound Announces $25 Million Strategic Private Placement Financing
2024-05-29 11:00 ET
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
2024-05-22 12:00 ET
MediWound to Report First Quarter 2024 Financial Results
2024-04-25 12:00 ET
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
2024-03-21 11:00 ET
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
2024-03-14 12:00 ET
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
2024-02-12 12:00 ET
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
2024-02-05 13:00 ET
MediWound to Participate in Two Upcoming Investor Conferences
2024-01-09 12:00 ET
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
2023-12-28 12:00 ET
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
2023-12-21 13:00 ET
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
2023-11-21 12:02 ET
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
2023-11-21 12:00 ET
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
2023-11-14 13:02 ET
MediWound to Report Third Quarter 2023 Financial Results
2023-11-13 12:00 ET
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
2023-11-08 12:00 ET
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
2023-10-11 10:00 ET
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
2023-10-09 11:34 ET
MediWound Deploys NexoBrid® for Emergency Supply
2023-09-26 11:00 ET
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
2023-09-21 10:00 ET
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
2023-09-11 12:00 ET
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
2023-09-05 12:00 ET
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-15 20:03 ET
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
2023-08-15 20:02 ET
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
2023-08-07 12:00 ET
MediWound to Report Second Quarter 2023 Financial Results
2023-08-01 11:30 ET
MediWound Announces Commercial Launch of NexoBrid® in Japan
2023-07-10 11:30 ET
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2023-07-03 11:00 ET
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
2023-06-14 12:00 ET
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
2023-05-30 11:00 ET
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
2023-05-12 12:00 ET
MediWound to Report First Quarter 2023 Financial Results
2023-05-09 11:30 ET
MediWound Announces an Additional $10 Million Award from BARDA
2023-05-09 ET
MediWound Announces an Additional $10 Million Award from BARDA
2023-04-26 12:00 ET
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
2023-03-16 11:10 ET
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
2023-03-16 11:00 ET
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
2023-03-06 12:00 ET
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
2023-03-02 13:47 ET
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
2023-02-23 13:00 ET
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
2023-02-07 21:01 ET
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
2023-02-07 ET
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
2023-02-03 15:30 ET
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
2023-02-03 ET
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
2022-12-23 13:00 ET
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
2022-12-20 13:00 ET
MediWound Strengthens European Presence of NexoBrid®
2022-12-19 12:00 ET
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2022-12-13 10:30 ET
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
2022-12-05 21:05 ET
MediWound Announces a 1-for-7 Reverse Share Split
2022-11-15 12:00 ET
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
2022-11-09 13:00 ET
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
2022-11-03 12:00 ET
MediWound to Report Third Quarter 2022 Financial Results
2022-10-25 11:00 ET
MediWound Announces Formation of Strategic Advisory Board
2022-10-18 11:00 ET
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
2022-10-07 10:00 ET
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
2022-09-22 12:02 ET
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
2022-09-20 11:00 ET
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
2022-09-12 12:00 ET
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
2022-08-09 11:30 ET
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
2022-08-08 20:05 ET
MediWound Enhances Its Board and Executive Leadership Team
2022-08-01 12:00 ET
MediWound Schedules Second Quarter 2022 Financial Results
2022-07-11 11:00 ET
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2022-07-08 12:00 ET
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
2022-07-07 11:00 ET
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
2022-07-05 20:05 ET
MediWound to Host a Key Opinion Leader Investor Day on EscharEx
2022-06-30 11:00 ET
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
2022-05-17 11:01 ET
MediWound Announces CEO Transition
2022-05-17 11:00 ET
MediWound Reports First Quarter 2022 Financial Results
2022-05-12 11:00 ET
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
2022-05-10 20:01 ET
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
2022-04-12 12:00 ET
MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
2022-03-29 12:00 ET
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
2022-03-22 20:05 ET
MediWound Announces Exercise of Over-Allotment Option
2022-03-21 11:30 ET
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
2022-03-17 11:00 ET
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-10 22:05 ET
MediWound Announces Closing of Public Offering of Ordinary Shares
2022-03-10 13:00 ET
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
2022-03-03 13:30 ET
MediWound Announces Pricing of Public Offering of Ordinary Shares
2022-03-02 21:24 ET
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
2022-03-01 13:00 ET
MediWound to Present at Upcoming Investor Conferences in March
2022-02-17 11:00 ET
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
2022-02-14 14:02 ET
MediWound to Present at Upcoming Investor Conferences in February
2022-02-10 12:00 ET
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
2022-01-24 11:00 ET
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
2021-12-20 12:00 ET
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
2021-12-06 12:00 ET
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
2021-11-18 12:30 ET
EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
2021-11-16 12:00 ET
MediWound Reports Third Quarter 2021 Financial Results
2021-11-04 12:00 ET
MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021
2021-10-04 11:30 ET
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
2021-09-03 20:14 ET
MediWound to Present at Upcoming Investor Conferences
2021-08-10 11:00 ET
MediWound Reports Second Quarter Financial Results
2021-08-02 20:05 ET
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
2021-07-28 11:00 ET
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
2021-07-26 11:00 ET
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2021-07-20 11:00 ET
MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
2021-07-09 12:00 ET
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
2021-06-09 20:30 ET
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
2021-06-07 11:00 ET
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
2021-05-05 11:00 ET
MediWound Reports First Quarter 2021 Financial Results
2021-04-26 20:20 ET
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
2021-04-22 11:30 ET
MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
2021-03-24 20:05 ET
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
2021-02-25 21:01 ET
MediWound to Participate in Upcoming March Investment Conferences
2021-02-25 12:00 ET
MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-02-22 11:30 ET
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
2021-02-16 21:05 ET
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
2021-02-10 21:15 ET
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-01-11 12:00 ET
MediWound Provides Progress Update on Its EscharEx Clinical Development Program
2021-01-05 12:00 ET
MediWound to Participate in Upcoming Investor Conferences in January
2020-12-21 12:30 ET
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
2020-12-14 21:15 ET
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
2020-11-10 12:00 ET
MediWound Reports Third Quarter 2020 Financial Results
2020-11-02 21:01 ET
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
2020-10-28 11:00 ET
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
2020-10-14 12:00 ET
MediWound Studying the Effect of EscharEx on Biofilm Burden
2020-09-03 13:00 ET
MediWound to Present at Upcoming Investor Conferences in September
2020-08-06 11:00 ET
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-28 12:00 ET
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
2020-06-30 11:00 ET
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
2020-05-20 11:00 ET
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-13 12:00 ET
MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
2020-05-04 11:30 ET
MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
2020-04-27 11:00 ET
MediWound Strengthens Board of Directors
2020-03-30 11:30 ET
MediWound Provides Corporate Update Related to COVID-19 Pandemic
2020-03-03 11:00 ET
BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid Deployment
2020-02-28 21:18 ET
MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
2020-02-25 12:00 ET
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
2020-02-18 13:00 ET
MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
2020-01-13 13:00 ET
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
2020-01-06 11:30 ET
BARDA Initiates the Procurement of NexoBrid for Emergency Response
2020-01-02 12:30 ET
MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical
2019-12-03 12:30 ET
MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
2019-11-14 12:00 ET
MediWound Reports Third Quarter 2019 Financial Results
2019-11-06 13:00 ET
MediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14
2019-03-12 11:00 ET
MediWound Announces Executive Leadership Changes
2019-01-22 11:30 ET
MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

SEC forms

Show financial reports only

SEC form 6
2026-05-27 11:05 ET
MediWound published news for 2026 q1
SEC form 6
2026-05-27 11:05 ET
MediWound published news for 2026 q1
SEC form 6
2026-04-02 20:19 ET
MediWound published news for 2026 q1
SEC form 6
2026-04-02 20:19 ET
MediWound published news for 2026 q1
SEC form 6
2026-03-30 21:29 ET
MediWound published news for 2025 q4
SEC form 6
2026-03-30 21:29 ET
MediWound published news for 2025 q4
SEC form 6
2026-03-30 21:29 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 20
2026-03-05 07:30 ET
MediWound published news for 2025 q4
SEC form 6
2026-03-05 07:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-03-05 07:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-02-19 21:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-01-15 21:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-01-15 21:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-01-15 21:05 ET
MediWound published news for 2025 q4
SEC form 6
2026-01-12 12:08 ET
MediWound published news for 2025 q4
SEC form 6
2026-01-12 12:08 ET
MediWound published news for 2025 q4
SEC form 6
2025-11-20 07:04 ET
MediWound published news for 2025 q3
SEC form 6
2025-11-20 07:04 ET
MediWound reported for 2025 q3
SEC form 6
2025-09-30 20:38 ET
MediWound published news for 2025 q2
SEC form 6
2025-09-30 20:38 ET
MediWound published news for 2025 q2
SEC form 6
2025-09-30 20:38 ET
MediWound published news for 2025 q2
SEC form 6
2025-09-29 12:49 ET
MediWound published news for 2025 q2
SEC form 6
2025-09-29 12:49 ET
MediWound published news for 2025 q2
SEC form 6
2025-08-19 11:00 ET
MediWound published news for 2025 q2
SEC form 6
2025-08-14 11:05 ET
MediWound published news for 2025 q2
SEC form 6
2025-08-14 11:05 ET
MediWound reported for 2025 q2
SEC form 6
2025-08-14 11:05 ET
MediWound reported for 2025 q2
SEC form 6
2025-05-21 11:07 ET
MediWound published news for 2025 q1
SEC form 6
2025-05-21 11:07 ET
MediWound reported for 2025 q1
SEC form 6
2025-05-15 20:35 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 20
2025-03-19 11:15 ET
MediWound published news for 2024 q4
SEC form 6
2025-03-19 11:05 ET
MediWound published news for 2024 q4
SEC form 6
2025-03-19 11:05 ET
MediWound reported for 2024 q4
SEC form 6
2025-02-12 12:05 ET
MediWound published news for 2024 q4
SEC form 6
2025-02-12 12:05 ET
MediWound published news for 2024 q4
SEC form 6
2024-11-26 07:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-26 07:05 ET
MediWound reported for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-08-15 16:20 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-15 16:20 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:21 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:21 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-05 08:53 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-05 08:53 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-16 07:35 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-16 07:35 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-09 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 07:05 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 07:05 ET
MediWound reported for 2024 q1
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 20
2024-03-21 08:08 ET
MediWound published news for 2023 q4
SEC form 6
2024-03-21 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-03-21 07:05 ET
MediWound reported for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-09 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-09 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-08 07:00 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-08 07:00 ET
MediWound published news for 2023 q4
SEC form 6
2023-12-28 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-12-28 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-11-21 07:05 ET
MediWound reported for 2023 q3
SEC form 6
2023-11-21 07:03 ET
MediWound published news for 2023 q3
SEC form 6
2023-11-13 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-09-26 16:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-09-21 06:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-08-15 16:10 ET
MediWound reported for 2023 q2
SEC form 6
2023-08-15 16:01 ET
MediWound published news for 2023 q2
SEC form 6
2023-08-02 08:00 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-17 16:01 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-10 07:35 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-03 07:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-05-31 16:10 ET
MediWound published news for 2023 q1
SEC form 6
2023-05-31 16:05 ET
MediWound published news for 2023 q1
SEC form 6
2023-05-30 07:05 ET
MediWound reported for 2023 q1
SEC form 6
2023-05-09 07:35 ET
MediWound published news for 2023 q1
SEC form 6
2023-04-20 16:06 ET
MediWound published news for 2023 q1
SEC form 6
2023-03-16 07:15 ET
MediWound reported for 2022 q4
SEC form 6
2023-03-16 07:05 ET
MediWound reported for 2022 q4
SEC form 6
2023-03-16 07:02 ET
MediWound published news for 2022 q4
SEC form 20
2023-03-16 00:00 ET
MediWound published news for 2022 q4
SEC form 6
2023-02-13 08:00 ET
MediWound published news for 2022 q4
SEC form 6
2023-02-07 16:06 ET
MediWound published news for 2022 q4
SEC form 6
2023-01-09 06:09 ET
MediWound published news for 2022 q4
SEC form 6
2022-12-29 13:52 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-23 08:10 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-20 07:01 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-19 07:28 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-05 16:10 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-28 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-15 07:05 ET
MediWound reported for 2022 q3
SEC form 6
2022-11-14 16:06 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-09 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-10-21 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-09-26 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-09-20 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-09 00:00 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-08 16:10 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-03 07:35 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-19 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-12 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-11 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-07 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-06-30 07:05 ET
MediWound published news for 2022 q1
SEC form 6
2022-06-09 07:04 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-17 07:06 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-17 07:05 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-12 07:04 ET
MediWound published news for 2022 q1
SEC form 6
2022-03-22 16:10 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-17 07:08 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-17 07:05 ET
MediWound published news for 2021 q4
SEC form 20
2022-03-17 00:00 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-03 16:09 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-02 16:33 ET
MediWound published news for 2021 q4
SEC form 6
2022-02-10 07:05 ET
MediWound published news for 2021 q4
SEC form 6
2022-01-24 06:05 ET
MediWound published news for 2021 q4
SEC form 6
2021-12-20 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-12-06 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-11-16 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-08-10 00:00 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-28 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-26 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-20 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-06-29 08:54 ET
MediWound published news for 2021 q1
SEC form 6
2021-06-15 16:06 ET
MediWound published news for 2021 q1
SEC form 6
2021-05-05 16:15 ET
MediWound published news for 2021 q1
SEC form 6
2021-05-05 07:05 ET
MediWound published news for 2021 q1
SEC form 6
2021-04-22 07:39 ET
MediWound published news for 2021 q1
SEC form 6
2021-02-25 07:53 ET
MediWound published news for 2020 q4
SEC form 6
2021-02-25 07:05 ET
MediWound published news for 2020 q4
SEC form 6
2021-02-22 06:30 ET
MediWound published news for 2020 q4
SEC form 6
2021-01-11 07:05 ET
MediWound published news for 2020 q4
SEC form 6
2020-11-10 07:06 ET
MediWound published news for 2020 q3
SEC form 6
2020-10-30 16:30 ET
MediWound published news for 2020 q3
SEC form 6
2020-10-28 07:00 ET
MediWound published news for 2020 q3